NERV - Minerva Neurosciences, Inc.
| Previous Close | 9.00 |
| Open | 8.95 |
| Bid | 8.60 x 800 |
| Ask | 8.65 x 800 |
| Day's Range | 8.45 - 9.05 |
| 52 Week Range | 4.80 - 10.15 |
| Volume | 86,993 |
| Avg. Volume | 159,490 |
| Market Cap | 335.181M |
| Beta | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.33 |
- GlobeNewswire•22 days ago
Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central ...
- GlobeNewswire•22 days ago
Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
WALTHAM, Mass., May 30, 2018-- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, today ...
- GlobeNewswire•last month
Recent Analysis Shows Capital Senior Living, Digital Realty Trust, Minerva Neurosciences, Zix, First Merchants, and PennantPark Investment Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, May 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capital ...
- MarketWatch•last month
Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug
Minerva Neurosciences Inc. shares rose 5.4% in premarket trade on Thursday after results from a phase 2b trial for a schizophrenia drug were published in the peer-reviewed The Journal of Clinical Psychiatry. ...
- GlobeNewswire•last month
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp...
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has published online results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101). The results also demonstrated that cognitive improvements correlate with previously reported improvements in negative symptoms. Roluperidone is a novel compound with affinities for 5HT2A and sigma2 receptors and no direct binding to dopamine receptors.
- GlobeNewswire•last month
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has published online results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101). The results also demonstrated that cognitive improvements correlate with previously reported improvements in negative symptoms. Roluperidone is a novel compound with affinities for 5HT2A and sigma2 receptors and no direct binding to dopamine receptors.
- Thomson Reuters StreetEvents•last month
Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
Q1 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•2 months ago
Minerva Neurosciences: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 32 cents. Minerva Neurosciences shares have risen 14 percent since the beginning of the year. The stock has fallen nearly ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass., May 03, 2018-- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported ...
- GlobeNewswire•2 months ago
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
Management to host conference call WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of ...
- GlobeNewswire•2 months ago
Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com.
- GlobeNewswire•2 months ago
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Multi-center trial to enroll approximately 324 patients at approximately 40 clinical sites in U.S. and Europe WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), ...
- GlobeNewswire•2 months ago
Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
WALTHAM, Mass., April 09, 2018-- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced ...
- GlobeNewswire•3 months ago
Detailed Research: Economic Perspectives on Altisource Residential, Sykes Enterprises, Gibraltar Industries, Silicon Laboratories, TC PipeLines, LP, and Minerva Neurosciences — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•3 months ago
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV).
- GlobeNewswire•3 months ago
Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
WALTHAM, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-18 12:30pm GMT
Q4 2017 Minerva Neurosciences Inc Earnings Call
- Associated Press•3 months ago
Minerva Neurosciences posts 4Q profit
The Waltham, Massachusetts-based company said it had net income of less than 1 cent on a per-share basis. Losses, adjusted for pretax gains, were 24 cents per share. For the year, the company reported ...
- GlobeNewswire•3 months ago
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward Management to host conference call today at 8:30 ...
- ACCESSWIRE•3 months ago
Minerva Neurosciences Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Minerva Neurosciences Inc (NASDAQ: NERV ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 8:30 AM Eastern ...
- GlobeNewswire•4 months ago
Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
Management to host conference call WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of ...
